The DOI matches its Crossref record; 132 of the 133 references it cites were found in a registry or an index.
Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease
Open accessAbstract
Nonalcoholic fatty liver disease (NAFLD) is a liver manifestation of metabolic syndrome. Overconsumption of high-fat diet (HFD) and increased intake of sugar-sweetened beverages are major risk factors for development of NAFLD. Today the most commonly consumed sugar is high fructose corn syrup. Hepatic lipids may be derived from dietary intake, esterification of plasma free fatty acids (FFA) or hepatic de novo lipogenesis (DNL). A central abnormality in NAFLD is enhanced DNL. Hepatic DNL is increased in individuals with NAFLD, while the contribution of dietary fat and plasma FFA to hepatic lipids is not significantly altered. The importance of DNL in NAFLD is further established in mouse studies with knockout of genes involved in this process. Dietary fructose increases levels of enzymes involved in DNL even more strongly than HFD. Several properties of fructose metabolism make it particularly lipogenic. Fructose is absorbed via portal vein and delivered to the liver in much higher concentrations as compared to other tissues. Fructose increases protein levels of all DNL enzymes during its conversion into triglycerides. Additionally, fructose supports lipogenesis in the setting of insulin resistance as fructose does not require insulin for its metabolism, and it directly stimulates SREBP1c, a major transcriptional regulator of DNL. Fructose also leads to ATP depletion and suppression of mitochondrial fatty acid oxidation, resulting in increased production of reactive oxygen species. Furthermore, fructose promotes ER stress and uric acid formation, additional insulin independent pathways leading to DNL. In summary, fructose metabolism supports DNL more strongly than HFD and hepatic DNL is a central abnormality in NAFLD. Disrupting fructose metabolism in the liver may provide a new therapeutic option for the treatment of NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Fructose enhances its own metabolism by upregulating ketohexokinase (KHK), which is elevated in MASLD; diets high in both fat and fructose worsen MASLD, but fructose alone more strongly induces DNL enzymes like ACC1, FASN, and stearoyl-CoA desaturase 1 (SCD1) compared to HFDs [13].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [13]
In the citing paper
“Fructose enhances its own metabolism by upregulating ketohexokinase (KHK), which is elevated in MASLD; diets high in both fat and fructose worsen MASLD, but fructose alone more strongly induces DNL enzymes like ACC1, FASN, and stearoyl-CoA desaturase 1 (SCD1) compared to HFDs [13].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [13]
In the citing paper
“Fructose enhances its own metabolism by upregulating ketohexokinase (KHK), which is elevated in MASLD; diets high in both fat and fructose worsen MASLD, but fructose alone more strongly induces DNL enzymes like ACC1, FASN, and stearoyl-CoA desaturase 1 (SCD1) compared to HFDs [13].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [13]
In the citing paper
“Patients with MASLD often show reduced hepatic ATP [13].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [13]
In the citing paper
“Importantly, DAG buildup, not TG, is linked to hepatic IR via PKC activation.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Sontrop, J. M., Dixon, S. N., Garg, A. X., Jiménez, I. B., Dohein, O., Huang, S. S., & Clark, W. F. (2013) · American Journal of Nephrology · doi:10.1159/000350377 · Cited by 5,903
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Critical nodes in signalling pathways: insights into insulin action
Taniguchi, C. M., Emanuelli, B., & Kahn, C. R. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1837 · Cited by 2,760
Self-citationTriglyceride accumulation protects against fatty acid-induced lipotoxicity
Listenberger, L. L., Han, X., Lewis, S. E., Cases, S., Farese, R. V., Ory, D. S., & Schaffer, J. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630588100 · Cited by 2,075
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.001 · Cited by 1,805
Stanhope, K. L., Schwarz, J. M., Keim, N. L., Griffen, S. C., Bremer, A. A., Graham, J. L., Hatcher, B., Cox, C. L., Dyachenko, A., Zhang, W., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37385 · Cited by 1,765
Loomba, R. S., & Sanyal, A. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.171 · Cited by 1,732
Insulin Receptor Signaling in Normal and Insulin-Resistant StatesPreprint
Boucher, J., Kleinridders, A., & Kahn, C. R. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009191 · Cited by 1,550
Self-citation
Cited by
Sorted by citations
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
The role of the gut microbiota in NAFLD
Leung, C., Rivera, L., Furness, J. B., & Angus, P. W. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.85 · Cited by 1,020
Fructose and sugar: A major mediator of non-alcoholic fatty liver disease
Jensen, T., Abdelmalek, M. F., Sullivan, S. A., Nadeau, K. J., Cree‐Green, M., Roncal, C., Nakagawa, T., Kuwabara, M., Sato, Y., Kang, D., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.01.019 · Cited by 993
2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis
Le, M. H., Yeo, Y. H., Li, X., Li, J., Zou, B., Wu, Y., Ye, Q., Huang, D. Q., Zhao, C., Zhang, J., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.002 · Cited by 711
Immune cell-mediated features of non-alcoholic steatohepatitis
Huby, T., & Gautier, E. L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00639-3 · Cited by 573
Recent insights into the pathogenesis of nonalcoholic fatty liver disease
Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573
Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate
Zhao, S., Jang, C., Liu, J., Uehara, K., Gilbert, M., Izzo, L., Zeng, X., Trefely, S., Fernandez, S., Carrer, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2101-7 · Cited by 553
Pathophysiology of obesity and its associated diseases
Jin, X., Qiu, T., Li, L., Yu, R., Chen, X., Li, C., Proud, C. G., & Jiang, T. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.012 · Cited by 603
Impaired adipogenesis and dysfunctional adipose tissue in human hypertrophic obesity
Hammarstedt, A., Gogg, S., Hedjazifar, S., Nerstedt, A., & Smith, U. (2018) · Physiological Reviews · doi:10.1152/physrev.00034.2017 · Cited by 462
Dietary modifications for enhanced cancer therapy
Kanarek, N., Petrova, B., & Sabatini, D. M. (2020) · Nature · doi:10.1038/s41586-020-2124-0 · Cited by 418
The links between gut microbiota and obesity and obesity related diseases
Geng, J., Ni, Q., Sun, W., Li, L., & Feng, X. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112678 · Cited by 422
Fructose Consumption, Lipogenesis, and Non-Alcoholic Fatty Liver Disease
ter Horst, K. W., & Serlie, M. J. M. (2017) · Nutrients · doi:10.3390/nu9090981 · Cited by 379
Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling
Softic, S., Gupta, M. K., Wang, G.-X., Fujisaka, S., O'Neill, B. T., Rao, T. N., Willoughby, J. L. S., Harbison, C. E., Fitzgerald, K. J., Ilkayeva, O., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94585 · Cited by 353
Self-citationPathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Manne, V., Handa, P., & Kowdley, K. V. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.08.007 · Cited by 347
Fructose stimulated de novo lipogenesis is promoted by inflammation
Todoric, J., Di Caro, G., Reibe, S., Henstridge, D. C., Green, C. R., Vrbanac, A., Ceteci, F., Conche, C., McNulty, R., Shalapour, S., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0261-2 · Cited by 328
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
Chen, H., Tan, H., Wan, J., Zeng, Y., Wang, J., Wang, H., & Lu, X. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108391 · Cited by 342
Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease
Targher, G., & Byrne, C. D. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.16 · Cited by 315
High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanisms
Lian, C.-Y., Zhai, Z., Li, Z., & Wang, L. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109199 · Cited by 325
Dietary Fructose and the Metabolic Syndrome
Taskinen, M., Packard, C. J., & Borén, J. (2019) · Nutrients · doi:10.3390/nu11091987 · Cited by 310
Fructose and NAFLD: The Multifaceted Aspects of Fructose Metabolism
Jegatheesan, P., & Bandt, J. P. D. (2017) · Nutrients · doi:10.3390/nu9030230 · Cited by 294
Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?
Febbraio, M. A., Reibe, S., Shalapour, S., Ooi, G., Watt, M. J., & Karin, M. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.10.012 · Cited by 250
Fructose and hepatic insulin resistance
Softic, S., Stanhope, K. L., Boucher, J., Divanovic, S., Lanaspa, M. A., Johnson, R. J., & Kahn, C. R. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1711360 · Cited by 257
Self-citationMonounsaturated Fatty Acids in Obesity-Related Inflammation
Ravaut, G., Légiot, A., Bergeron, K., & Mounier, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010330 · Cited by 272
Softic, S., Meyer, J. G., Wang, G.-X., Gupta, M. K., Batista, T. M., Lauritzen, H. P. M. M., Fujisaka, S., Serra, D., Herrero, L., Willoughby, J., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.003 · Cited by 227
Self-citationLinden, A. G., Li, S., Choi, H. Y., Fang, F., Fukasawa, M., Uyeda, K., Hammer, R. E., Horton, J. D., Engelking, L. J., & Liang, G. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m081836 · Cited by 243
Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD)
Saeed, A., Dullaart, R. P. F., Schreuder, T. C. M. A., Blokzijl, H., & Faber, K. N. (2017) · Nutrients · doi:10.3390/nu10010029 · Cited by 237
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments
Peng, C. Y., Stewart, A. G., Woodman, O. L., Ritchie, R. H., & Qin, C. X. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.603926 · Cited by 239
Metabolic drivers of non-alcoholic fatty liver disease
Bence, K. K., & Birnbaum, M. J. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101143 · Cited by 230
Tillman, E. J., & Rolph, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601290 · Cited by 214
Insulin action at a molecular level – 100 years of progress
White, M. F., & Kahn, C. R. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101304 · Cited by 221
Self-citationCD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing
Zeng, H., Qin, H., Liao, M., Zheng, E., Luo, X., Xiao, A., Li, Y., Chen, L., Wei, L., Zhao, L., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101428 · Cited by 211
Qu, X., & Donnelly, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218191 · Cited by 210
Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia
Morrow, M. R., Batchuluun, B., Wu, J., Ahmadi, E., Leroux, J. M., Mohammadi-Shemirani, P., Desjardins, E. M., Wang, Z., Tsakiridis, E. E., Lavoie, D. C. T., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.05.004 · Cited by 199
Intestinal Absorption of Fructose
Ferraris, R. P., Choe, J.-Y., & Patel, C. R. (2018) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-082117-051707 · Cited by 180
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Do, A., Zahrawi, F. M., & Mehal, W. Z. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01084-2 · Cited by 206
The small intestine shields the liver from fructose-induced steatosis
Jang, C., Wada, S., Yang, S. H., Gosis, B. S., Zeng, X., Zhang, Z., Shen, Y., Lee, G., Arany, Z. P., & Rabinowitz, J. D. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0222-9 · Cited by 175
Scorletti, E., & Byrne, C. D. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.03.001 · Cited by 168
Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship
Karkucińska‐Więckowska, A., Simões, I. C. M., Kalinowski, P., Lebiedzińska, M., Zieniewicz, K., Milkiewicz, P., Górska‐Ponikowska, M., Pinton, P., Malik, A. N., Krawczyk, M. J., et al. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13622 · Cited by 172
Metabolic liver disease in diabetes – From mechanisms to clinical trials
Dewidar, B., KAHL, S., Pafili, K., & Roden, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154299 · Cited by 167
Muriel, P., López‐Sánchez, P., & Ramos‐Tovar, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136969 · Cited by 171
Nonalcoholic Fatty Liver Disease in Children
Mann, J. P., Valenti, L. V. C., Scorletti, E., Byrne, C. D., & Nobili, V. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1627456 · Cited by 169
Importance of Nutrients and Nutrient Metabolism on Human Health.
Chen, Y., Michalak, M., & Agellon, L. B. (2018) · Europe PMC (PubMed Central) · Cited by 155
Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD)
Syed‐Abdul, M. M. (2023) · Metabolites · doi:10.3390/metabo14010012 · Cited by 166
Fougerat, A., Montagner, A., Loiseau, N., Guillou, H., & Wahli, W. (2020) · Cells · doi:10.3390/cells9071638 · Cited by 150
Dietary Fructose and Fructose-Induced Pathologies
Jung, S., Bae, H., Song, W., & Jang, C. (2022) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-062220-025831 · Cited by 158
Portincasa, P., Khalil, M., Mahdi, L., Perniola, V., Idone, V., Graziani, A., Baffy, G., & Ciaula, A. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115640 · Cited by 167
Yahoo, N., Dudek, M., Knolle, P. A., & Heikenwälder, M. F. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.033 · Cited by 147
Ultraprocessed Food: Addictive, Toxic, and Ready for Regulation
Lustig, R. H. (2020) · Nutrients · doi:10.3390/nu12113401 · Cited by 154
Intestinal Fructose and Glucose Metabolism in Health and Disease
Merino, B., Fernández-Díaz, C. M., Cózar‐Castellano, I., & Perdomo, G. (2019) · Nutrients · doi:10.3390/nu12010094 · Cited by 147
Influence of Dietary Macronutrients on Liver Fat Accumulation and Metabolism
Parry, S. A., & Hodson, L. (2017) · Journal of Investigative Medicine · doi:10.1136/jim-2017-000524 · Cited by 141
Corte, K. W. D., Perrar, I., Penczynski, K. J., Schwingshackl, L., Herder, C., & Buyken, A. E. (2018) · Nutrients · doi:10.3390/nu10050606 · Cited by 138
Evolving Role for Pharmacotherapy in NAFLD/NASH
Attia, S. L., Softic, S., & Mouzaki, M. (2020) · Clinical and Translational Science · doi:10.1111/cts.12839 · Cited by 131
Self-citationHerrera‐Balandrano, D. D., Chai, Z., Hutabarat, R. P., Trust Beta, Feng, J., Ma, K., Li, D., & Huang, W. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102100 · Cited by 137
da Silva-Santi, L. G., Antunes, M. M., Caparroz‐Assef, S. M., Carbonera, F., Masi, L. N., Curi, R., Visentainer, J. V., & Bazotte, R. B. (2016) · Nutrients · doi:10.3390/nu8110682 · Cited by 121
Taskinen, M., Söderlund, S., Bogl, L. H., Hakkarainen, A., Matikainen, N., Pietiläinen, K. H., Räsänen, S., Lundbom, N. M. I., Björnson, E., Eliasson, B., et al. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12632 · Cited by 122
Singh, A. K., Chaube, B., Zhang, X., Sun, J., Citrin, K. M., Canfrán-Duque, A., Aryal, B., Rotllan, N., Varela, L., Lee, R. G., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140989 · Cited by 115
Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota
Doulberis, M., Kotronis, G., Gialamprinou, D., Kountouras, J., & Katsinelos, P. (2017) · Metabolism · doi:10.1016/j.metabol.2017.03.013 · Cited by 117
MicroRNA-27a regulates hepatic lipid metabolism and alleviates NAFLD via repressing FAS and SCD1
Zhang, M., Sun, W., Zhou, M., & Tang, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-15141-x · Cited by 113
Li, Y., Qiao, J., Wang, B., Bai, M., Shen, J.-D., & Cheng, Y. (2018) · Nutrients · doi:10.3390/nu10081024 · Cited by 114
Li, W., Yang, H., Zhao, Q., Wang, X., Zhang, J., & Zhao, X. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b02523 · Cited by 100
Emerging role of aging in the progression of NAFLD to HCC
He, Y., Su, Y., Duan, C., Wang, S., He, W. G., Zhang, Y., An, X., & He, M. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101833 · Cited by 100
Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies
Fang, T., Wang, H., Pan, X., Little, P. J., Xu, S., & Weng, J. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.65044 · Cited by 107
Fructose metabolism, cardiometabolic risk, and the epidemic of coronary artery disease
Mirtschink, P., Jang, C., Arany, Z. P., & Krek, W. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx518 · Cited by 95
Rumanova, V. S., Okuliarová, M., & Zeman, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155478 · Cited by 100
Lau, L. H. S., & Wong, S. H. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-8684-7_9 · Cited by 93
Longitudinal associations between ultra-processed foods and blood lipids in childhood
Leffa, P. D. S., Hoffman, D. J., Rauber, F., Sangalli, C. N., Valmórbida, J. L., & Vítolo, M. R. (2020) · British Journal Of Nutrition · doi:10.1017/s0007114520001233 · Cited by 100
Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease
Paglialunga, S., & Dehn, C. A. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0321-5 · Cited by 93
Kim, J., Kang, J., Kang, Y.-L., Woo, J. J., Kim, Y., Huh, J., & Park, J. (2020) · Nature Communications · doi:10.1038/s41467-020-19263-1 · Cited by 95
The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease
Jennison, E., & Byrne, C. D. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0129 · Cited by 91
Stanhope, K. L., Goran, M. I., Bosy‐Westphal, A., King, J. C., Schmidt, L. A., Schwarz, J., Stice, E. M., Sylvetsky, A. C., Turnbaugh, P. J., Bray, G. A., et al. (2018) · Obesity Reviews · doi:10.1111/obr.12699 · Cited by 90
The Role of SCAP/SREBP as Central Regulators of Lipid Metabolism in Hepatic Steatosis
Chandrasekaran, P., & Weiskirchen, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021109 · Cited by 95
Kazierad, D. J., Chidsey, K., Somayaji, V. R., Bergman, A. J., Birnbaum, M. J., & Calle, R. A. (2021) · Med · doi:10.1016/j.medj.2021.04.007 · Cited by 85
Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases
Guerra, J. V. D. S., Dias, M. M. G., Brilhante, A. J. V. C., Terra, M. F., García‐Arévalo, M., & Figueira, A. C. M. (2021) · Nutrients · doi:10.3390/nu13082830 · Cited by 92
Cohen, C. C., Li, K. W., Alazraki, A. L., Beysen, C., Carrier, C., Cleeton, R. L., Dandan, M., Figueroa, J., Knight‐Scott, J., Knott, C. J., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci150996 · Cited by 86
Fernandes‐da‐Silva, A., Miranda, C. S., Santana-Oliveira, D. A., Oliveira-Cordeiro, B., Rangel-Azevedo, C., Silva-Veiga, F. M., Martins, F. F., & Souza‐Mello, V. (2021) · European Journal of Nutrition · doi:10.1007/s00394-021-02542-y · Cited by 86
Rao, G., Peng, X., Li, X., An, K., He, H., Fu, X., Li, S., & An, Z. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1294267 · Cited by 93
Jayakumar, S., & Loomba, R. S. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15314 · Cited by 87
Kord‐Varkaneh, H., Salehi‐Sahlabadi, A., Tinsley, G. M., Santos, H. O., & Hekmatdoost, A. (2022) · Nutrition · doi:10.1016/j.nut.2022.111847 · Cited by 89
Cheng, C., Li, Z., Zhao, X., Liao, C., Quan, J., Bode, A. M., Cao, Y., & Luo, X. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.172922 · Cited by 83
Truong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
“In addition, drugs targeting the DNL pathways, such as ci-trate-isocitrate carrier inhibitors [75], ACLY inhibitors [13,141], ACC inhibitors (alone or in combination with DGAT inhibitors) [105,142,143], FASN inhibitors [144], and adiponectin receptor 1/2 agonists have shown preclinical and/or…”
InfluentialLiu, S., Gao, Z., He, W., Wu, Y., Liu, J., Zhang, S., Yan, L., Mao, S., Shi, X., Fan, W., et al. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.10.270 · Cited by 79
Goss, A. M., Dowla, S. A., Pendergrass, M., Ashraf, A. P., Bolding, M., Morrison, S. A., Amerson, A., Soleymani, T., & Gower, B. A. (2020) · Pediatric Obesity · doi:10.1111/ijpo.12630 · Cited by 78
Tissue-Specific Fructose Metabolism in Obesity and Diabetes
Helsley, R. N., Moreau, F., Gupta, M. K., Radulescu, A., DeBosch, B. J., & Softic, S. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01342-8 · Cited by 80
Self-citationLiverSex Computational Model: Sexual Aspects in Hepatic Metabolism and Abnormalities
Tomaš, T. C., Urlep, Ž., Moškon, M., Mraz, M., & Rozman, D. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00360 · Cited by 73
Fructose drives de novo lipogenesis affecting metabolic health
Geidl, B., & Gerber, P. A. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0270 · Cited by 84
Oral Diseases Associated with Nonalcoholic Fatty Liver Disease in the United States
Weintraub, J. A., Mitnik, G. L., & Dye, B. A. (2019) · Journal of Dental Research · doi:10.1177/0022034519866442 · Cited by 70
Park, E., Lee, Y., Kim, S. M., Park, G.-S., Lee, Y. H., Jeong, D. Y., Kang, J., & Lee, H. (2020) · Nutrients · doi:10.3390/nu12020542 · Cited by 70
Sun, S., Araki, Y., Hanzawa, F., Umeki, M., Kojima, T., Nishimura, N., Ikeda, S., Mochizuki, S., & Oda, H. (2021) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2021.108621 · Cited by 69
Bathish, B., Robertson, H., Dillon, J. F., Dinkova‐Kostova, A. T., & Hayes, J. D. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.06.226 · Cited by 70
Bergman, A. J., Carvajal‐Gonzalez, S., Tarabar, S., Saxena, A. R., Esler, W. P., & Amin, N. B. (2020) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.782 · Cited by 68
Jeyapal, S., Kona, S. R., Mullapudi, S. V., Putcha, U. K., Gurumurthy, P., & Ibrahim, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-29222-y · Cited by 68
Fatty liver and FGF21 physiology
Maratos–Flier, E. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.05.006 · Cited by 66
Brandon, H., & Yan, L. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s198968 · Cited by 67
Fructose impairs fat oxidation: Implications for the mechanism of western diet-induced NAFLD
Inci, M. K., Park, S., Helsley, R. N., Attia, S. L., & Softic, S. (2022) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2022.109224 · Cited by 65
Self-citationNew Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article
Ebrahimi, H., Naderian, M., & Sohrabpour, A. A. (2016) · Middle East Journal of Digestive Diseases · doi:10.15171/mejdd.2016.29 · Cited by 61
Nutrition as Metabolic Treatment for Anxiety
Norwitz, N. G., & Naidoo, U. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.598119 · Cited by 64
Role of targeting TLR4 signaling axis in liver-related diseases
Tang, Y., Zhu, L., Tao, Y., Lu, W., & Cheng, H. S. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154410 · Cited by 60
Hepatic glucagon action: beyond glucose mobilization
Kajani, S., Laker, R. C., Ratkova, E. L., Will, S., & Rhodes, C. J. (2024) · Physiological Reviews · doi:10.1152/physrev.00028.2023 · Cited by 65
Wang, X., Rao, H., Liu, F., Wei, L., Li, H., & Wu, C. (2021) · Cells · doi:10.3390/cells10123300 · Cited by 66
Metadata
- Authors
- Softic, S., Cohen, D. E., & Kahn, C. R.
- Affiliations
- Boston Children's Hospital (US)
- Brigham and Women's Hospital (US)
- Joslin Diabetes Center (US)
- Corresponding author
- Kahn, C. Ronald
- Venue
- Digestive Diseases and Sciences
- Published
- 2016-02-08
- Volume
- 61
- Issue
- 5
- Pages
- 1282-1293
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- PMC
- PMC4838515
- OpenAlex
- W2286797029
- Cited by
- 709
- References
- 133
- Citations by year
- 2026: 52 · 2025: 76 · 2024: 88 · 2023: 78 · 2022: 92 · 2021: 79 · 2020: 88 · 2019: 57 · 2018: 44 · 2017: 42 · 2016: 13
- FWCI
- 7.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK031036, R01 DK033201, K12 HD000850, R37 DK048873, R01 DK056626, R01 DK103046)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- non-alcoholic fatty liver disease, dietary fructose, hepatic de novo lipogenesis, high fructose corn syrup, high-fat diet, sugar-sweetened beverages, insulin resistance, SREBP-1c, endoplasmic reticulum stress, uric acid, mitochondrial fatty acid oxidation, reactive oxygen species, hepatic lipid metabolism, metabolic syndrome
- MeSH terms
- Diet, Fructose, Humans, Liver, Lipogenesis, Non-alcoholic Fatty Liver Disease, High Fructose Corn Syrup
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
